Abstract
Patients admitted with prediabetes and atrial fibrillation are at high risk for major adverse cardiac or cerebrovascular events independent of confounding variables. The shared pathophysiology between these three serious but common diseases and their association with atherosclerotic cardiovascular risk factors establish a vicious circle culminating in high atherogenicity. Because of that, it is of paramount importance to perform risk stratification of patients with prediabetes to define phenotypes that benefit from various interventions. Furthermore, stress hyperglycemia assessment of hospitalized patients and consensus on the definition of prediabetes is vital. The roles lifestyle and metformin play in prediabetes are well established. However, the role of glucagon-like peptide agonists and metabolic surgery is less clear. Prediabetes is considered an intermediate between normoglycemia and diabetes along the blood glucose continuum. One billion people are expected to suffer from prediabetes by the year 2045. Therefore, real-world randomized controlled trials to assess major adverse cardiac or cerebrovascular event risk reduction and reversal/prevention of type 2 diabetes among patients are needed to determine the proper interventions.